Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody ...

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely ...

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...

Hong Kong-based biopharma company Akeso (HKEX: 9926) announced that its global first-in-class PD-1/VEGF bispecific antibody, ...

A good update was also provided here a few months ago, whereby the independent data monitoring committee (IDMC) already recommended dosing of the second cohort of this study. As I stated in the ...

The policy mandates the formation of a State Data Steering Committee (SDSC), which will coordinate and monitor the implementation of this policy in close collaboration with all departments and ...

DAR ES SALAAM, April 17 (Xinhua) -- Somalia has officially launched its national monitoring committee on the elimination of non-tariff barriers, marking a major milestone in its integration into ...

An independent data monitoring committee (iDMC) that regularly reviews all of the data from the trial recently held their scheduled meeting and made a recommendation to modify the trial design. To cut ...